Wayne State start-up receives prestigious Luis Villalobos Award
RetroSense Therapeutics, LLC, a Wayne State University start-up biotechnology company, has received the Luis Villalobos Award from the Angel Capital Association (ACA), the world's leading professional association for angel investors. Zhuo-Hua Pan, Ph.D., scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute, the Edward T. and Ellen K. Dryer Endowed Professor in Vision and Blindness Research in the Department of Ophthalmology, and professor of anatomy and cell biology in Wayne State University's School of Medicine, along with colleagues at Salus University in Pennsylvania, developed the breakthrough optogenetic approaches to restore vision through the use of a light-sensitive protein from green algae to confer new light sensitivity in the retinas in which rod and cone photoreceptors have degenerated. As one of the advantages, the optogenetic approaches have the potential to treat all forms of blindness due to the death of photoceptors, independent of causative gene or mutation. "RetroSense Therapeutics received their nomination because advanced gene therapy is a difficult field for angel investors or underfunded entrepreneurs," said Stephen M. Lanier, vice president for Research at Wayne State University. "The founders of RetroSense and Dr. Pan have stayed focused on their important work to restore sight. Their work is extraordinary for optogenetics, a field that assumes a long and costly clinical process. They are most deserving of this prestigious recognition."